Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04010877 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04010877 · ClinicalTrials.gov record · last posted 2026-08-24

Multiple CAR-T Cell Therapy Targeting AML

Name: Multiple CAR-T Cell Therapy Targeting AML — clinical trial record (NCT04010877)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusTerminated

PhasePhase 1/2

SponsorShenzhen Geno-Immune Medical Institute

Started2025-08-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and refractory AML. The study also aims to learn more about the function of CAR T cells and their persistency in AML patients.

Protocol amendment history 3 changes detected by DataLookout

2026-08-25

Trial terminated

2026-08-25

Primary completion moved earlier: 2028-07-31 → 2026-07-01

2026-08-25

Completion moved earlier: 2029-12-31 → 2026-07-31

Trial Details

NCT Number	NCT04010877
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Acute Myeloid Leukemia
Enrollment	10 participants
Start Date	2025-08-01
Primary Completion	2026-07-01 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-24